CD274 and non-small cell lung carcinoma: In a phase III trial, CheckMate-057, nivolumab was associated with a longer progression-free survival (PFS) and OS than docetaxel in pretreated non-squamous (non-Sq) NSCLC patients exhibiting high PD-L1 expression [18].